var data={"title":"Treatment protocols for soft tissue and bone sarcoma","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment protocols for soft tissue and bone sarcoma</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-soft-tissue-and-bone-sarcoma/contributors\" class=\"contributor contributor_credentials\">Tim Brenner, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-soft-tissue-and-bone-sarcoma/contributors\" class=\"contributor contributor_credentials\">Shrina Duggal, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-soft-tissue-and-bone-sarcoma/contributors\" class=\"contributor contributor_credentials\">Jim Natale, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-soft-tissue-and-bone-sarcoma/contributors\" class=\"contributor contributor_credentials\">Scott M Wirth, PharmD, BCOP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-soft-tissue-and-bone-sarcoma/contributors\" class=\"contributor contributor_credentials\">John W Mucenski, PharmD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-soft-tissue-and-bone-sarcoma/contributors\" class=\"contributor contributor_credentials\">Diane MF Savarese, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-soft-tissue-and-bone-sarcoma/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Mar 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Oct 27, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H8525761\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following material represents a subset of chemotherapy regimens that are used for the treatment of adult patients with soft tissue and bone sarcomas. <strong>This is</strong> <strong>not an exhaustive list</strong>; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with sarcomas. Additional regimens may be added over time, particularly as treatment for bone and soft tissue sarcoma evolves.</p><p>This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with sarcomas. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=treatment-of-locally-recurrent-and-unresectable-locally-advanced-soft-tissue-sarcoma-of-the-extremities\" class=\"medical medical_review\">&quot;Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=systemic-treatment-of-metastatic-soft-tissue-sarcoma\" class=\"medical medical_review\">&quot;Systemic treatment of metastatic soft tissue sarcoma&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=adjuvant-and-neoadjuvant-chemotherapy-for-soft-tissue-sarcoma-of-the-extremities\" class=\"medical medical_review\">&quot;Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=chemotherapy-and-radiation-therapy-in-the-management-of-osteosarcoma\" class=\"medical medical_review\">&quot;Chemotherapy and radiation therapy in the management of osteosarcoma&quot;</a>.)</p><p/><p>These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</p><p class=\"headingAnchor\" id=\"H8525768\"><span class=\"h1\">REGIMENS</span></p><p class=\"headingAnchor\" id=\"H85120418\"><span class=\"h2\">Bone sarcomas</span></p><p class=\"headingAnchor\" id=\"H825943302\"><span class=\"h3\">Doxorubicin plus cisplatin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F87182\" class=\"graphic graphic_table graphicRef87182 \">table 1</a>)</p><p class=\"headingAnchor\" id=\"H463344128\"><span class=\"h3\">Methotrexate plus doxorubicin and cisplatin (MAP)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F87346\" class=\"graphic graphic_table graphicRef87346 \">table 2</a>)</p><p class=\"headingAnchor\" id=\"H85120378\"><span class=\"h2\">Soft tissue sarcomas</span></p><p class=\"headingAnchor\" id=\"H936759827\"><span class=\"h3\">Doxorubicin (Adriamycin) plus ifosfamide and mesna (AIM 60/6)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F56240\" class=\"graphic graphic_table graphicRef56240 \">table 3</a>)</p><p class=\"headingAnchor\" id=\"H936759852\"><span class=\"h3\">Doxorubicin (Adriamycin) plus ifosfamide and mesna (AIM 75/9)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F67985\" class=\"graphic graphic_table graphicRef67985 \">table 4</a>)</p><p class=\"headingAnchor\" id=\"H936759877\"><span class=\"h3\">Doxorubicin (Adriamycin) plus ifosfamide and mesna (AIM 75/10)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F81370\" class=\"graphic graphic_table graphicRef81370 \">table 5</a>)</p><p class=\"headingAnchor\" id=\"H936759902\"><span class=\"h3\">Gemcitabine plus docetaxel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F58713\" class=\"graphic graphic_table graphicRef58713 \">table 6</a>)</p><p class=\"headingAnchor\" id=\"H7613292\"><span class=\"h3\">Pegylated liposomal doxorubicin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F88268\" class=\"graphic graphic_table graphicRef88268 \">table 7</a>)</p><p class=\"headingAnchor\" id=\"H1955795169\"><span class=\"h3\">Weekly paclitaxel for angiosarcoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F95037\" class=\"graphic graphic_table graphicRef95037 \">table 8</a>)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 85692 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H8525761\" id=\"outline-link-H8525761\">INTRODUCTION</a></li><li><a href=\"#H8525768\" id=\"outline-link-H8525768\">REGIMENS</a><ul><li><a href=\"#H85120418\" id=\"outline-link-H85120418\">Bone sarcomas</a><ul><li><a href=\"#H825943302\" id=\"outline-link-H825943302\">- Doxorubicin plus cisplatin</a></li><li><a href=\"#H463344128\" id=\"outline-link-H463344128\">- Methotrexate plus doxorubicin and cisplatin (MAP)</a></li></ul></li><li><a href=\"#H85120378\" id=\"outline-link-H85120378\">Soft tissue sarcomas</a><ul><li><a href=\"#H936759827\" id=\"outline-link-H936759827\">- Doxorubicin (Adriamycin) plus ifosfamide and mesna (AIM 60/6)</a></li><li><a href=\"#H936759852\" id=\"outline-link-H936759852\">- Doxorubicin (Adriamycin) plus ifosfamide and mesna (AIM 75/9)</a></li><li><a href=\"#H936759877\" id=\"outline-link-H936759877\">- Doxorubicin (Adriamycin) plus ifosfamide and mesna (AIM 75/10)</a></li><li><a href=\"#H936759902\" id=\"outline-link-H936759902\">- Gemcitabine plus docetaxel</a></li><li><a href=\"#H7613292\" id=\"outline-link-H7613292\">- Pegylated liposomal doxorubicin</a></li><li><a href=\"#H1955795169\" id=\"outline-link-H1955795169\">- Weekly paclitaxel for angiosarcoma</a></li></ul></li></ul></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/85692|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/87182\" class=\"graphic graphic_table\">- Doxorubin plus cisplatin osteosarcoma</a></li><li><a href=\"image.htm?imageKey=ONC/87346\" class=\"graphic graphic_table\">- MAP osteosarcoma young adults and children</a></li><li><a href=\"image.htm?imageKey=ONC/56240\" class=\"graphic graphic_table\">- AIM 60_6</a></li><li><a href=\"image.htm?imageKey=ONC/67985\" class=\"graphic graphic_table\">- AIM 75_9</a></li><li><a href=\"image.htm?imageKey=ONC/81370\" class=\"graphic graphic_table\">- AIM 75_10</a></li><li><a href=\"image.htm?imageKey=ONC/58713\" class=\"graphic graphic_table\">- Gem plus doc for advanced sarcoma</a></li><li><a href=\"image.htm?imageKey=ONC/88268\" class=\"graphic graphic_table\">- PLD for soft tissue sarcoma</a></li><li><a href=\"image.htm?imageKey=ONC/95037\" class=\"graphic graphic_table\">- Weekly paclitaxel for unresectable angiosarcoma</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=adjuvant-and-neoadjuvant-chemotherapy-for-soft-tissue-sarcoma-of-the-extremities\" class=\"medical medical_review\">Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chemotherapy-and-radiation-therapy-in-the-management-of-osteosarcoma\" class=\"medical medical_review\">Chemotherapy and radiation therapy in the management of osteosarcoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-treatment-of-metastatic-soft-tissue-sarcoma\" class=\"medical medical_review\">Systemic treatment of metastatic soft tissue sarcoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-locally-recurrent-and-unresectable-locally-advanced-soft-tissue-sarcoma-of-the-extremities\" class=\"medical medical_review\">Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities</a></li></ul></div></div>","javascript":null}